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COMPLETE NUCLEOTIDE SEQUENCE OF PstI-L FRAGMENT
OF TANAPOX VIRUS GENOMIC DNA
Sarah J. Neering, M.S.
Western Michigan University, 1993
Tanapox virus (TPV), of the genus Yatapoxvirus, is a human
poxvirus that was originally isolated from the Tana River Valley in Kenya
in 1962. TPV produces a mild disease characterized by a short febrile
illness associated with one or more nodular skin lesions. Although there
have been limited studies on TPV, other poxviruses such as vaccinia
virus, have been extensively characterized and their genomic DNAs
sequenced. In order to examine the molecular features of TPV, we have
cloned approximately 17% of the genomic DNA. TPV DNA was digested
with Pstl restriction endonuclease and cloned into pUC19. The Pstl-L
fragment, composed of 2,108 base pairs, has been sequenced. Computer
analyses show there are several potential open reading frames (ORF)
within this fragment. The largest ORF consists of 239 amino acids (27
kDa). None of the ORFs analyzed show a high degree of homology with
other poxviruses.
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INTRODUCTION
Tanapox virus (TPV) is the prototype of the Yatapoxvirus genus
belonging to the family Poxvirdae.

Like vaccina virus (VV), the most

extensively studied poxvirus, TPV contains a large, linear, double stranded
DNA genome. The size of TPV genomic DNA is approximately 145 kbp
(Knight, Novembre, Brown, Goldsmith & Espositio, 1989). In comparing
the genomic size of TPV to VV, which has a genomic size of 192 kbp
(Goebel, Johnson, Perkus, Davis, Winslow, & Paoletti, 1990) potentially
coding for 200-300 polypeptides (Essani & Dales, 1979), TPV may possibly
encode between 150-200 polypeptides. Unlike VV, little is known about
the genomic organization of TPV or the molecular mechanisms
governing viral gene expression.
TPV was originally isolated in 1962 from human lesions in an
outbreak of disease among natives of the Tana River Valley in Kenya
(Downie, Taylor-Robinson, Caunt, Nelson, Manson-Bahr & Matthews,
1971).

TPV is believed to be transmitted to man from monkeys via

mosquitoes (Downie, Taylor-Robinson, Caunt, Nelson, Manson-Bahr &
Matthews, 1971; Manson-Bahr & Downie, 1973). The same virus gave rise
to epidemic infections in macaques monkeys (Macaca mulatta) in primate
centers in Oregon, Texas and California during 1965-66 (Crandell, Casey &
Brumlow, 1969; Hall & McNulty, 1967).

Animal handlers at these

locations contracted TPV through abrasions or cuts incurred from the
monkeys.
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TPV produces a mild infection in humans characterized by a short
febrile illness lasting for approximately 2 to 4 days. During this period one
or more nodular skin lesions appear at the site of entry. The lesion begins
as a small papule and develops into a raised circular vesicle that becomes
umbilicated (Casey, Woodruff & Butcher, 1967; Crandell, Casey &
Brumlow, 1969; Downie, Taylor-Robinson, Caunt, Nelson, Manson-Bahr
& Matthews, 1971; Espana, Brayton & Ruebner, 1971; Hall & McNulty,
1967; Nicholas & McNulty, 1968). The disease is self-limiting and full
recovery occurs within 6 to 8 weeks. There have been no reported cases of
reinfection (Jezek, Arita, Szczeniowski, Paluku, Ruti & Nakano, 1985).
TPV may provide opportunities to elucidate molecular
mechanisms viruses employ to interact with the human immune system,
because it is a primate virus which does infect humans. It has been shown
in three other poxviruses [cowpox virus (Ray et al., 1992), myxoma virus
(Upton, Mossman & McFadden, 1992) and shope virus (Smith et al., 1990)]
that these viruses produce anti-cytokine proteins which may increase
virulence by inhibiting host immune cell function.

Therefore, the

purpose of this study was to further characterize TPV at the DNA sequence
level and eventually determine how TPV proteins differ from other well
characterized poxvirus polypeptides.

In order to do this we took

advantage of data previously obtained by Knight et al. (1989). These
studies described three DNA restriction maps (Bamffi, Mlul and Pstl). The
Pstl restriction endonuclease was used in our studies. Pstl digests the TPV
genome into 15 fragments. These fragments are alphabetized from A to N
based on their size, A being the largest fragment and N the smallest.

REVIEW OF LITERATURE
General Characteristics of Tanapox Virus
Tanapox virus (TPV) has been classified in the genus Yatapoxvirus
of the family Poxviridae. TPV, a large enveloped DNA virus, appears oval
or brick-shaped under electron microscopy. Thin sectioned virions show a
lipoprotein bilayer surrounding a core that appears biconcave with two
structures of unknown function, called lateral bodies, within the
concavities (Casey, Woodruff & Butcher, 1967; Espana, Brayton, &
Ruebner, 1971).

The virion contains a non-infectious, linear, double

stranded DNA genome of approximately 145,000 base pairs (bp). The
terminal ends of the genome are joined by hair-pin loops (Knight,
Novembre, Brown, Goldsmith & Esposito, 1989). Like other poxviruses,
TPV replicates within the cytoplasm of infected cells (Buller & Palumbo,
1991).
Historical Background
TPV, an endemic, zoonotic virus of equatorial Africa, was originally
isolated from human skin biopsy specimens in 1962 (Downie, Taylor
Robinson, Caunt, Nelson, Manson-Bahr & Matthews, 1971). The disease
was first seen in 1957 in a village on the flood plains of the lower reaches
of the Tana River· in Kenya.

In 1962, a more wide spread epidemic
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occurred along the middle areas of the Tana River between Garrissa and
Garsen (Downie, Taylor-Robinson, Caunt, Nelson, Manson-Bahr &
Matthews, 1971). In 1965 and 1966, animal handlers at primate centers in
California, Oregon and Texas contracted the disease through cuts and/or
abrasions inflicted while handling infected monkeys or cleaning cages that
housed these monkeys (Casey, Woodruff & Butcher, 1967; Crandell, Casey
& Brumlow, 1969; Espana, Brayton & Ruebner, 1971; Hall & McNulty,
1967; Nicholas & McNulty, 1968). The virus isolated from these monkeys
was shown to be identical to TPV isolated from natives in 1962 (Downie &
Espana, 1971).

The fact that the same virus was responsible for the

outbreak in the primate centers in the United States and in natives of
Africa had an important relation to the epidemiology of the disease.
Viral Polypeptides
Knight et al. (1989) purified TPV particles by velocity sedimentation
in 20-40% (w/w) sucrose gradients followed by a CsCl density gradient.
This resulted in generating two viral particle sedimentation bands, one
band of aggregated particles that sedimented at 1.25 g/ml in the CsCl
gradient and the second nonaggregated band at 1.27 g/ml. Sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of each viral band
showed approximately 55 proteins ranging in size from 11 kDa to 200 kDa.
There were slight differences between the two protein patterns of TPV
particles sedimenting at different densities.

In addition to common

proteins, the slower sedimenting virions (1.25 g/ml) contained 12 proteins
that were not present in the faster sedimenting virions. A 30 kDa protein
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and a 28 kDa protein were common to both viral patterns, but the 30 kDa
protein was markedly decreased in the faster sedimenting virions while
the 28 kDa protein was decreased in the slower sedimenting virions.
There were two proteins (40 kDa and 29 kDa) unique to the faster
sedimenting virions. These differences were most likely due to the fact
that the slower sedimenting viral particles were double-enveloped virions
while the faster sedimenting particles were single-enveloped virions. The
differences in sedimentation densities appeared to be a result of whether
the virion was double-enveloped or single-enveloped, whereas the
differences in protein patterns could be a result of the second envelope
having different proteins than the first envelope.
Viral DNA Analysis
The approximate size of TPV genomic DNA has been previously
calculated to be 145 kbp via estimates of DNA digested fragment molecular
sizes and field inversion gel electrophoresis. Restriction maps of the TPV
genome were established by end-fragment determination and through
analysis of overlap cross-hybridization of isolated, individual Pstl, Mlul,
and BamHI viral DNA fragments (Knight, Novembre, Brown, Goldsmith
& Esposito, 1989).
Clinical Features of Infection
TPV produces a mild disease in humans characterized by a short
febrile illness that lasts for approximately 2 to 4 days. Severe headache,
backache and pronounced prostration may occur during this period. One
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or more pock-like skin lesions, occurring primarily on exposed areas of the
skin (i.e. arms, hands and legs), have been reported (Casey, Woodruff &
Butcher, 1967; Crandell, Casey & Brumlow, 1969; Downie, Taylor
Robinson, Caunt, Nelson, Manson-Bahr & Matthews, 1971; Espana,
Brayton & Ruebner, 1971; Hall & McNulty, 1967; Nicholas & McNulty,
1968). The lesion starts as a papule and develops into raised circular
vesicle that becomes umbilicated. No pustulation has been recorded and
usually only a single lesion occurs. In some cases swelling of regional
lymph nodes and inflammation of lymph ducts occurred (McNulty,
Lobitz, Hu, Maruffo & Hall, 1968). The lesions spontaneously disappear
within 6 to 8 weeks and there have been no reports of reinfection (Jezek,
Arita, Szczeniowski, Paluku, Ruti & Nakano, 1985).
Histopathology
Lesions in humans are characteriz�d by epidermal spinoses with
extension of the epidermal ridges. Follicular epithelium and epidermal
cells show vacuolization within their cytoplasm.
appear thin, elongated, and filled with fluid.

The dermal papilla

Capillaries within the

dermal papilla become swollen and congested with red blood cells. The
congested capillaries are usually seen at the tips of the papilla which are
covered by a layer of necrotic epidermal cells (McNulty, Lobitz, Hu,
Maruffo & Hall, 1968).
In early lesions only the upper epidermal layer is affected. As the
lesion progresses the dermis also becomes involved. In early stages, where
swelling occurs with infiltration of immune cells, the vascular
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involvement can be quite extensive with destruction of blood cells that
results in fibrosis and blockage of the lumen (McNulty, Lobitz, Hu,
Maruffo & Hall, 1968).
Lesions in monkeys, the natural host of TPV, show an increase in
the thickness of the epidermis that extends down the hair shafts and into
the sebaceous glands forming masses of epidermal cells in the dermis.
Swelling of both the cytoplasm and nucleus of cells occurs. Sometimes
discrete cytoplasmic eosinophilic inclusions have been seen in all cell
layers of the epidermis, follicular cells and basal cells of the sebaceous
gland (Hall & McNulty, 1967). In the outer epidermal layer, cells are
frequently necrotic with sloughing in some areas. The necrotic crust is
composed of keratin, leukocyte discharge and dead unkeratinized
epidermal cells. There are a moderate number of inflammatory cells,
mostly neutrophils, in necrotic and degenerate regions.

Both

mononuclear and polymorphonuclear cells are present in perivascular
areas of the dermis and subcutaneous tissues (Crandell, Casey & Brumlow,
1969). The mode of transmission of TPV among monkeys has not been
identified but direct contact or an insect vector has been suggested.
Although death has not been associated with the disease, the extent of
secondary infections has determined the clinical course of disease.
Epidemiology
The epidemiology of TPV has not been fully elucidated. Specific
characteristics have been deduced from a study conducted in Northern
Zaire over a 5 year period (Jezek, Arita, Szczeniowski, Paluku, Ruti &
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Nakano, 1985). There appeared to be no discrimination between age, sex
and occupation of infected people. The majority of people infected had
been immunized against small pox indicating that the small pox vaccine
offered no protection against TPV.
TPV infections were more frequent during November through
March. This time period coincided with the period that mosquitoes and
other blood-sucking insects were active, suggesting mode of transmission
could possibly have been arthropod in nature.
The mode of transmission between animals and from animals to
man is presently unknown.

However, the rapid transmission among

monkeys housed together suggests a common source or direct contact
between affected and susceptible monkeys. There have been no reported
cases indicating that TPV can be transmitted directly from person to
person. It has been suggested that TPV can be transmitted from monkeys
to humans through arthropod vectors, specifically culicine mosquitoes
(Downie, Taylor-Robinson, Caunt, Nelson, Manson-Bahr & Matthews,
1971; Manson-Bahr & Downie, 1973).
Serological Studies
Serologically, TPV has minimal cross-reactivity to only one other
pox virus pathogenic to humans, Yaba monkey tumor virus (YMTV)
(Downie & Espana, 1972; Nicholas & McNulty, 1968). TPV and YMTV
share the same host range and are similar in shape, size and ultrastructure
(Casey, Woodruff & Butcher, 1967; Espana, Brayton & Ruebner, 1971).
However, lesions produced by these viruses differ in both histological and
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gross appearance. YMTV lesions in monkeys and humans are tumor-like
and involve mesodermal cells while TPV lesions affect primarily the
epidermis.
Monkeys recovering from either TPV or YMTV infections showed
partial cross-immunity. Studies with immune sera showed that following
absorption each virus possessed common ·as well as specific antigens
(Downie & Espana, 1973).
Analysis of sera collected from natives living in the Tana River
Valley in 1971 showed that TPV infections continued to occur in the area
since the outbreak in 1962 (Manson-Bahr & Downie, 1973).

The

examination of repeated serum samples from these natives indicated that
antibody to TPV was not detectable after 2 to 3 years. Further serological
surveys of the lower Tana River valley in 1976 confirmed the results
obtained in 1971 (Axford & Downie, 1979).

MATERIALS AND METHODS
Virus and Cell Lines
TPV was obtained from American Type Culture Collection,
Rockville, Maryland, and grown in monolayers of CV-1 monkey kidney
cells or Owl monkey kidney (OMK) cells.

Both types of cells were

maintained in Earle's minimum essential medium (MEM) containing
10% (v/v) heat-inactivated newborn calf serum, 2 mM glutamine and
antibiotics (100 units/ml penicillin G sodium, 100 µg/ml streptomycin
°

sulfate and 0.25 µg/ml amphotericin B). Cells were cultured at 37 in an
incubator with 5% CO2. Cells were infected with 1-2 plaque forming units
(pfu) per cell. Adsorption was carried out on a rocking platform at room
temperature for one hour. Following adsorption, TPV infected cells were
maintained in Earle's MEM containing 2% (v/v) heat-inactivated
°

newborn calf serum, 2 mM glutamine and antibiotics at 35 with 5% CO2.
TPV for further infections and tests was prepared from cultures of
CV-1 or OMK cells in 75 cm2 culture flasks. Infected cells were harvested
5-7 days post-infection using a rubber policeman and cells were pelleted by
centrifugation at 1500 xg (Sorvall RC-SB refrigerated superspeed centrifuge;
Sorvall type GSA rotor at 3000 rpm) for 20 minutes.

The pellet was

resuspended in sterile deionized water and freeze-thawed three times to
release intracellula� virus. Large cytoplasmic debris and nuclei were then
removed by centrifugation at 3000 xg (SS-34 Sorvall rotor at 5000 rpm).
The resulting supernatants were centrifuged at 85,000 xg (Beckman L8-70M
10
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ultracentrifuge; Ti-70.1 fixed angle rotor at 30,000 rpm) for 30 minutes to
pellet the virus. The virus pellet was resuspend in 10 mM Tris-HCl, pH
°

8.0, to a final concentration of l00X and stored at -20 .
Cloning of Tanapox Virus Genomic DNA
Restriction Enzyme Cleavage of DNA
TPV genomic DNA was kindly supplied by Dr. Joseph J. Esposito,
Centers for Disease Control, Atlanta, Georgia.

Pstl restriction

endonuclease (Gibco BRL, Gaithersburg, MD) was used to digest,
separately, lµg TPV genomic DNA and lµg pUC19 under the following
conditions: 5 units PstI (10 mM Tris-HCl, pH 7.4, 50 mM NaCl, 0.1 mM
EDTA, 1 mM DTT, 0.15% (v/v) TRITON X-100, 50% (v/v) glycerol) per µg
DNA, lX REact 2 buffer (50 mM Tris-HCl, pH 8.0, 10 mM MgCl2, 50 mM
NaCl) in a total volume of 10 µl with deionized water. The reactions were
°

incubated at 37 for 12-18 hours. Reactions were terminated by either heat
°

inactivation at 65 for 30 minutes or by addition of l0X stop solution (0.5
M EDTA, 65% sucrose, 0.2% bromophenol blue, 0.2% xylenecyanol).
Dephosphorylation of pUC19 and Ligation of Tanapox Pstl Fragments
Dephosphorylation of pUC19 was done using calf intestine
phosphatase (CIP) (Boehringer Mannheim, Indianapolis, IN) as suggested
by manufacturer. Briefly, 1 µl of CIP (1 µg/ml) was added to 3-5 µg of DNA
along with 1 µl of lOX CIP buffer (0.5 M Tris-HCl, pH 9.0, 10 mM MgCb, 1
mM ZnCl2, 10 mM spermidine) and brought up to a total volume of 10 µl
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with deionized water. The mixture was incubated at 37 for 15 minutes
°

then at 56 for an additional 15 minutes. Another aliquot of CIP was
added and the mixture reincubated as above. The reaction was terminated
°

by heating at 75 for 10 minutes.
Following dephosphorylation, Pstl digested pUC19 and TPV DNA
were purified, to remove the enzyme, using Geneclea� (Promega,
Madison, WI) following manufacturers instructions. Briefly, 3 volumes of
6M Nal was added to the digested DNA along with 5 µl of Glassmilk®.
The solution was vortexed and put on ice for 5 minutes with occasional
mixing. The suspension was briefly centrifuged, pelleted and washed 3
times with NEW® wash solution. The final pellet was resuspended in
deionized water equal to volume of pellet. The mixture was incubated at
°

45-55 for 2-3 minutes, centrifuged and the supernatant containing eluted
DNA was collected.
The heat inactivated mixture containing Pstl digested fragments of
TPV DNA were ligated into pUC19 as described in Maniatis (Maniatis,
Fritsch & Sambrook, 1989). Briefly, 2 µl of 1 unit/µl T4 DNA ligase (Gibco
BRL, Gaithsburg, MD), 1 µl of 10 mg/ml bovine serum albumin (BSA), 1
ul of 5X ligase buffer [0.25 M Tris-HCl, pH 7.6, 50 mM MgCh, 5 mM ATP, 5
mM DIT, 25% (w/v) PEG-8000] were added to a 1:5 mixture of pUC19-TPV
°

DNA. The reaction was incubated at 12 for 12-14 hours. The reaction was
°

terminated by heating at 75 for 10 minutes.
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Transformation
Ligated TPV DNA was transformed into commercially available
DH5cx-MCR competent cells (Gibco BRL, Gaithsburg, MD) by adding 5 µl of
°

ligation mixture to 50 µl of competent cells and incubating at 4 for 30
°

minutes. The mixture was then heated at 42 .for 45 seconds and returned
°

to 4 for 2 minutes. Nine hundred microliters of SOC medium (0.5% yeast
extract, 2% tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM
MgSO4, 20 mM glucose) was added to the chilled mixture and incubated at
°

37 in a shaker at 200 rpm for 1.5 hours. The suspension was then plated
out in triplicate on 2X YT (1.0 % yeast extract, 1.6 % tryptone, 85 mM NaCl,
1 % agar) plates containing 50 µg/ml ampicillin using 20 µl, 50 µl and 100
°

µl of the suspension. Plates were incubated at 37 for 18-24 hours. Three
hundred ampicillin resistant colonies were isolated.
Purification of Plasmid DNA
Plasmid DNA was extracted using the Magic Mini Prep DNA
Purification System (Promega, Madison, WI) following manufacturer's
instructions. Briefly, bacterial cultures were grown in 2X YT medium
containing 50 µg/ml ampicillin for 12-16 hours. Cells were pelleted by
centrifugation at 2000 xg (Damon/IEC PR-6000 centrifuge at 3000 rpm) for
5 minutes and resuspended in cell resuspension buffer (50 mM Tris-HCl,
pH 7.5, 10 mM EDTA, 100 µg/ml RNase A). The cells were lysed in a
solution of 0.2 M NaOH and 1% SDS, neutralized with 2.55 M KC2H3O2,
pH 4.8, and pelleted by centrifugation at 16,000 xg (Brinkman 5415C
eppendorf centrifuge at 14,000 rpm) for 5 minutes. The supernatant was
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mixed with a resin and applied to a mini-column. The plasmid DNA was
°

eluted from the column by addition of deionized water preheated to 65 .
Analysis of Plasmid DNA by Electrophoresis
and Southern Blotting
Plasmid DNA was digested using Pstl enzyme as described above.
The reactions were terminated by addition of l0X stop solution. The
samples were loaded onto a 0.7% agarose gel made with lX TBE (89 mM
Tris, 89 mM boric acid, 2 mM EDTA, pH 8.0) containing 1 µg/ml ethidium
bromide.

The gel was electrophoresed at 50 V for 18-24 hours.

Electrophoresis was in lX TBE solution, pH 8.0. After electrophoresis the
gel was placed under a UV light source and photographed through a red
filter with polaroid type 665 film (Polaroid Corporation, Cambridge, MA).
The gel was then denatured by submerging it in 0.5 M NaOH, 1.5 M NaCl
at room temperature for 1 hour with gentle shaking. The gel was then
neutralized in 1.0 M Tris-HCl, pH 7.4, 1.5 M NaCl for 1 hour and the
denatured DNA fragments transferred to a Biotrans nylon membrane
(ICN, Irvine, CA) using standard methods as described in Maniatis et al.
(1989).

The membrane was rinsed in 6x SSC (0.9 M NaCl, 99 mM
°

Na3C6HsO7 · 2H20, pH 7.0) for 5 minutes, baked at 80 for 2 hours in a
vacuum oven and then placed in a plastic bag.
Hybridization and Autoradiography
The probe used for hybridization was obtained by excision of the
Pstl-L fragment (2.1 kbp) from a 0.7% low melting point agarose gel. For
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each gram of agarose, 3 ml of deionized water was added. The mixture
was heated to 100° for 3-5 minutes and then aliquoted into 35 µl portions.
The DNA was labeled using the multiprime DNA labeling system
(Amersham, Arlington Heights, IL) following manufacturer's
°

instructions. Briefly, the DNA was denatured by heating at 100 for 5
°

minutes, cooled to 37 and the following ingredients were added: 2 µl of
BSA (10 mg/ml), 10 µl of Oligo-labeling buffer minus cytosine, 5 µl (30
µCi) 32p d-CTP (400 Ci/mmol) and 2 µl Klenow (10 units/ml).

The

mixture was incubated at room temperature for 12-18 hours.
Nylon membranes following transfer were prehybridized in 5-10 ml
of hybridizing solution (HS) containing 50% deionized formamide, 1 M
NaHPO4, pH 7.2, 5 M NaCl, 250 mM EDTA, 10 mg/ml denatured salmon
°

sperm DNA and 7% SDS (w /v) at 42 for 12-24 hours. The HS was then
replaced with 5-10 ml of fresh HS to which heat denatured 32P-labeled
probe of the Pstl-L fragment had been added. The nylon membrane was
°

incubated at 42 for 24 hours and then washed three times, 30 minutes
°

each, with 6x SSC, 0.5% SDS at 62 . The filter was then exposed to Kodak
X-Omat AR film (Eastman Kodak, Rochester, NY) for 3-4 days.
DNA Sequencing
Both strands of the 2.1 kbp Pstl-L fragment were sequenced using
the dideoxynucleotide chain termination-based Sequenase Version 2.0
sequencing kit (United States Biochemical Corporation, Cleveland, OH)
following manufacturer's instructions. Briefly, 1 µg of plasmid DNA
containing the Pstl-L fragment was denatured by adding 1 µl of 2 N
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NaOH and deionized water to a final volume of 5 µl and placed on ice
for 5 minutes. To this 1 µl of primer (200 ng/ml), 1.5 µl 3 M NaC2H3O2
and 28 µl ethanol (100%) were added and the mixture was put on dry
ice/ethanol for 20 minutes. The DNA/primer were pelleted and washed
once with 60 µl of 70% ethanol and vacuum dried.

The pellet was

°

resuspend in 5 µl annealing buffer (lX), heated to 65 for 2 minutes and
slowly cooled to room temperature. To the annealed template-primer
the following were added: 1 µl DTT (0.1 M), 2 µl labeling nucleotide mix
(1.5 µM dGTP, 1.5 µM dCTP, 1.5 µM dTTP), 1 µl Sequenase® enzyme and
1 µl (10 µCi) 3 2p d-ATP (400 Ci/mmol). Reactions were terminated by
adding the reaction mixture, in equal volumes, to each of 4
°

dideoxynucleotide termination mixtures and incubated at 37 for 3-5
minutes. The reaction mixture was further terminated by the addition
°

of 4 µl stop solution. The reaction mixtures were heated to 80-90 for 5
minutes prior to loading and run on a 8% acrylamide gel (acrylamide:bis
acrylamide ratio, 19:1) in lX TBE, at 40 Watts for 2.5 hours. The gel was
exposed to Kodak X-Omat film for 3-5 days. Sequencing of the complete
L fragment was done by walking along the insert using 20-22 base
primers.
Purificaton of Primers
Primers were obtained from National Biosciences, Plymouth, MN.
The primers were purified using a BioGel P4 (Bio-Rad Laboratories,
Richmond, CA) column. One gram of BioGel P4 was suspended in 50 ml
of 10 mM Tris-HCl, pH 7.4, and left at room temperature for 1 hour. The
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mixture was then poured into an Econo-column (Bio-Rad Laboratories,
Richmond, CA) and buffer (10 mM Tris-HCl, pH 7.4) was run through
for 1 hour before loading primers. The column dimensions were 14 cm
x 1 cm.
Primers were resuspended in 100 µl of buffer (10 mM Tris-HCl, pH
7.4) and loaded onto the column. The flow· rate of buffer through the
column was 2 ml per minute. The absorbance of the DNA eluting off
the column was monitored on an LC detector (Gilson, Middleton, WI).
Fractions were collected and samples were analyzed on a Gilford
Response spectrophotometer (Gilford Instrument Lab, Inc., Boston, MA)
at a wavelength of 260 nm. Primers were used at a concentration of 200
ng/ml.
Data Analysis
Sequence analysis and data bank searches were done on a VAX
2000 computer using the IntelliGenetics Suite version 5.35 software
(IntelliGenetics, Mountain View, CA).

Data bases searched were

University of Geneva protein data bank and Protein Identification
Resource data bank.

RESULTS
Cloning of the Tanapox Virus Genome
DNA restriction maps of TPV DNA have previously been
published (Knight, Novembre, Brown, Goldsmith & Esposito, 1989).
Using this information, we chose the restriction endonuclease Pstl because
it produced manageable size DNA fragments for cloning into pUC19.
TPV genomic DNA was digested with Pstl restriction endonuclease
and the resulting DNA fragments were 'shot-gun' cloned into pUC19.
The plasmids were then transformed into competent DH5aMCR cells as
described in Materials and Methods. A total of 300 ampicillin resistant
colonies were selected and purified plasmids obtained were restriction
digested with Pstl to determine which fragment of TPV DNA they
contained. Table 1 lists the clones and the Pstl fragment they contain. Of
the 300 colonies screened only 116 contained a Pstl TPV DNA fragment.
Figure 1 shows 6 of the 15 possible Pstl TPV DNA fragments that were
successfully cloned. Approximately 17% of the TPV genome has been
cloned. Lanes A and B are 0X 174-HaeIII digested and A-HindIII digested
markers, respectively. Lane C contains Pstl digested TPV genomic DNA
and Lane Dis Pstl digested pUC19. Lanes E through K show the TPV DNA
fragments obtained from cloning.
We then selected the 2.1 kbp L fragment (clone #36) to sequence and
analyze due to its relatively short length and proximity to the end of the
genome. The L fragment is towards the 5' end of the TPV genome and it
18
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Table 1
Identification of Clones Containing PstI
TPV Genomic DNA Fragments
TPV DNA Fragment
and MW (kbp)

Clone Number

F Fragment (9.0 kbp)

20,45,139

H Fragment (6.6 kbp)

45,66,67,119,385,489

J Fragment (5.0 kbp)

9, 44, 62,72,78,388,389,393,447,460,469,470,495,
501

L Fragment (2.1 kbp)

7, 10, 16, 22, 24, 28,32,34, 36, 42, 48, 85,92,101,102,
109, 113, 121, 130, 134, 300, 310, 311, 321, 324, 330,
334, 336, 341, 357, 364, 365, 374, 378, 382, 402, 442,
448,455,461,468,478,481,493,496,505

M Fragment (1.4 kbp)

3,26,55,96,111,125,145,309,316,318,323,340,344,
350, 366, 370, 380, 392, 403, 412, 423, 439, 452, 463,
476,487,490,498

N Fragment (1.1 kbp)

4,53,93,94,144,301,325,326,337,342,346,363,401,
409,445,462,471,497,506

has been previously reported that poxvirus genomes (e.g. vaccinia virus)
are organized with essential genes clustered in the middle whereas
virulence markers that govern pathogenesis tend to map towards the ends
of the genome (Traktman, 1990). Some of these virulence markers are
secreted proteins that enhance the ability of the virus to propagate in its
natural host.
Before sequencing the 2.1 kbp fragment, we did a Southern blot to
verify that the fragment we cloned into pUC 19 was in fact the TPV PstI-L
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fragment reported by Knight et al. (1989). Figure 2 shows the Southern
blot of the gel shown in Figure 1 using the cloned 2.1 kbp fragment as the
probe. Lane His the 2.1 kbp Pstl-L fragment which corresponds to the Pstl
L fragment of TPV genomic DNA in Lane C.
Sequencing of the 2.1 kbp Pstl-L Fragment
Sequencing of the Pstl-L fragment was accomplished by the
dideoxynucleotide chain termination method (Sanger, Nicklen &
Coulson, 1977). The complete sequence of the PstI-L fragment has been
obtained. The entire sequence contains 2,108 base pairs. Over 75% of the
sequence (bp 431 to 2108) was obtained from both strands, the remaining
25% (bp 1 to 430) from one. Figure 3 shows the complete nucleotide
sequence of the Pstl-L fragment. The fragment reads in the 5' to 3'
direction.

Bases are in groups of ten and the unconfirmed region is

underlined. Up primer sites are in bold. and down are in italics. The
names of the primers are above the sequence.
Analysis of the Pstl-L Fragment
The complete sequence of the PstI-L fragment was analyzed for
possible open reading frames (ORFs) using lntelliGenetics sorftware. The
sequence was translated in each of the six possible frames to locate
potential ORFs. There are 37 possible ORFs located within the Pstl-L
fragment and 1 ORF partially contained within the fragment that extends
toward the 3' end of the genome. In order to simplify our analysis, we
only analyzed ORFs that were 100 base pairs or more in length. Given this
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10
CTGCAGCTTT TTGCTATCAA GGTTATGTGT TTAACATCAA

50

GTGCCAAAAA AAAAATTAAT AATGTTAAAA TACCAATAAT

90

AGTATTACAT GGAATAAACG ATGTTATATG CGATGTAAAA

TP-1 UP
130
TGGTCAAAAT ATATAATTAA GAGCGTIGGA AGCTACGACA
170
ACAATAAA
ATTATACAAA GGTGCAAATC ATGACCTGCA
GA

210

TAGAGAAGTT GAAGATATTA GAGATACTGT ATTTAGCGAT
250

ATTAAAGTAT GGCTAATAAA TAGATCTAAA GTTAGTTACT

290

ATGATGTCTT AATATAAAAG TTAAAAATAA ACGCAACATC

330
TTTTAGACAT GAATAATCAC AAAAGTAAGT TGGCGTTTTG
370
TP-2 UP
TTACGCGTTT CCAACTGTCG GAACCGTAAC AAAAGGAATT

410

GTCACAGTTA AAGATGCAGA CTTTACAGTA 1111 l'ACCAG

Figure 3. DNA Sequence of the Pstl-L Fragment of TPV.
The 2.1 kbp P s t l-L fragment of TPV was sequenced using the
dideoxynucleotide chain termination method as described in Materials
and Methods. The sequence of the Pstl-L fragment is presented in the 5' to
3' directi_on. The :region not sequenced in both directions is underlined.
Up primer sites are in bold and down primer sites are in italics with the
name of primer above the sequence.
(Continued on next page)
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450

AGTITGGGTT AGAAGCATTA ATTGTTAACT ATT111CAGT
490

AAACGCAAAT ATAGCAGAAA AATTATCAAA AGAACTATCT
530

GGAAAAACCA TTAATGTACA AGTAATTAGA ACAGATAAAT
570

TP7-DOWN

610

TP-3 UP

TAAAAGGATA TGTTGATGTT CGACACATAA CATGATATTA
TAATATAATA TGTCATGTCA GTAATGCCGA TTTTTTATAT
650
AGAGAGTGGT ATACAAGATT ATTTTAATTA CCCTTTACAT
690

AGCACTATTT ACTTCTTAAA AGACGAAAAA AAGGTAAAGT
730

ATTTATTAGA TCATGGATAT GATATAAATC AAAAAGCAAA
770

TP6-DOWN

TAATTCTTTA ACTCCGCTTC ATTATGCAGT TTTAACTAAC
810

AATGTTGAAA TAGTTAAATT ATTAATATCA AAAGGTGTTA
850

TP-4 UP

ATGTTAATGC TACTGATAGA TACGGATGTT CTCCTCTATA
890

TTATTATATT ATGACTAAAA AGGAAAATTA TGAAATTATA
930

AAACTATTGT TGGACAACGG TGCAGATGTA AATGCTGTTT
970

CTAGCATACA GGAAAATGTA TTACATGCAT TTACAGAATA
(Continued on next page)
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1010

CGGATGTAAG AACACCGAGG TTITAAAAAC AATTATTAAA
TP5-DOWN

1050

AAAACTTACA ACATAAACTC AAAAAATAAG TGGGGTAAAA
1090

CTCCGTTAAA TTITGCTGTA GAAAAAGATA ATATGAATAT
TP-5 UP

1130

AATAAAAATA TTGTTACATT ATGGAGCTAA TCCII I IACA
1170

CTTTCAAATA ACATGGATAC ACTAATGCAT TGIIIIIIAA
1210

ACAACATAAA TTTGTTTAAA AAAGTAAAAC TGTTATTAGA
1250

TATTGGTTTA GATCCAAATA GTAAAAATAT AGACGGTGAT
1290

TCTCCATTAC ATAAGATATG TTCAGTAAAT CCAAGTTTAT
TP-4 DOWN

1330

AGACAGTCAG TTTATTAGTT AGTAAAGGAG CAAATGTAAA
1370

CTCGTTAAAC AATGATAAAA ATACACCTCT TCATGTGTAT
1410

ATGTATGAAT ATCCAGACAA ATTTTGCAAA AGCGTGTTTG
TP-6 UP

1450

IIIIIIIGCT CAAAAAGGGA GCTAACATAC ATATAAACAA
1490

TAAATATAAT AAACAACCGT TTAATATTTT ATCTTGTAAT
1530

TP-3 DOWN

AAAGAAATAA CTATTGATTT AATTGAATTG TTTATTAAAA
(Continued on next page)
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1570

TP-3A DOWN

AAAATGTACA TGTGAATAAT AAAAACGTGT

ACGGATATTC

1610

ACCTATTCAT AAI111ICAA ACAATCCAAA CATTGACATT
1650

GTAAAAAGAT GGCTGGATTA CGGAGCAAAT CCTAACGACA
1690

AAACCGTTAA TGGAGTAACC CCAGTGCATA TAAGTGCAAA
1730

TP-7UP

AAATAAAAAC ACAAATGTTT TTAAGTTAAT AGTAAGTAAT
TP2-00WN 1770

GGAGGTGATG TTAATGCTGT AGATCAATAT GGGAATACTC
1810

CATTGCACGA ATCTGTAGTT AATGAAAATA ATTTTAAAAT
1850

ATTTGCTTAG TTTAGGAGTT AAAGATGTAC CAAACAAACG
1890

TP-1 DOWN

"""""�

GGGAGAAACT GCTCTTIIIA AAGCAGTAAG ACATGACAAA
1930

TTAAATTCTG TTAAGTTI11 GTTACAACAA CAAAATAATT
1970

TTTTAAATTA TGTAACTAAT GATGGAAACA CATGTATTTC
2010

AGAATGCTTT GATACCTTCA ATGAAGCAAT TTTTAACGAA
2050

CTTATAATTA ACAGACCTAA TATTTCTACC ATGATCATTT
2090

2108

CGTTAAACAA AGTTAACAAA TACTGCAG - 3'
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criteria, there are 8 possible ORFs contained within the Pstl-L fragment
and 1 ORF extending towards the 3' end of the genome.
Figure 4 shows the ORFs and the respective sizes of the putative
polypeptides. The numbering of the ORFs was according to Rosel et al.
(1986), using the letter (L) to designate the Pst fragment in which they
originated and then numbering successively from left to right.

The

reading frame direction is indicated by adding a L (left) or R (right) after
the numbering.
Computer analysis enabled us to compare the amino acid sequences
of the putative polypeptides with the University of Geneva and Protein
Indentification Resources libraries. The FASTP program of Lipman and
Pearson (Lipman & Pearson, 1985) was used to analyze the data. Table 2
shows a list of the ORFs, their molecular weights (MW) and homologies
to other known proteins. The term homology is loosely defined as the
number of amino acids that match between the two proteins when they
are aligned. The program may introduce gaps within the amino acid
sequence to help align the proteins.

The ORFs may also only be

homologous to a small portion of a larger protein.
The amino acid comparison revealed that most of the ORFs within
the Pstl-L fragment have some degree of homology to proteins that
function in cellular growth and development. ORFs Pstl-LSL and -L6R
show homology to insulin-like growth factor of rat (Shimatsu & Rotwein,
1987) and transforming growth factor f.s-5 of frog, respectively (Kondaiah et
al., 1990). The largest ORF (27 kDa) Pst-L4R shows homology to the Ml
protein of VV (30% in 40 amino acids), which is involved in drug
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resistance to a-amanitin (Tamin, Villarreal, Weinrich & Hruby, 1988), and
also to human erythrocyte ankryin (27%) which contains repeated
structures that have homology to tissue differentiation and cell-cycle
control proteins (Lux, John & Bennett, 1990).
Table 2
Amino Acid Comparison of the Putative Polypeptides
to Protein Data Bases
ORF

MW (kDa)

LlR

11

30% to K4 protein of VV
25% to A42R protein of VV

L2R

10

27% to Glutamine receptor of human, mouse
and rat
25% to ATP-dependent proteinase Ia in E.coli

I.3L

4.4

31% to alpha amino butyric acid receptor of rat
27% to DNA binding protein of human
cytomegalovirus
27% to RNA directed DNA polymerase in E.
c oli

L4R

27

31% to Baml-Il ORF13 protein of fowlpox
virus
30% to Ml protein of VV
27% to human erythrocyte ankyrin
25% to B4R protein of VV
24% to Hindill C protein of VV
23% to host range protein of cowpox virus

Percent Homology
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Table 2-Continued
ORF MW (kbp)

Percent Homology

ISL

4.6

35% to ULlO protein of human
cytomegalovirus
30% to Insulin-like growth factor IA precursor
of rat
27% to hypothetical protein of VV (mRNA
capping enzyme)

L6R

4.2

31% to human rhinovirus 14 genome
polyprotein
25% to transforming growth factor beta-5
precursor of frog

L7R

17

26% to Ml protein of VV
26% to human erythrocyte ankyrin
25% to B4R protein of VV

L8R

L9L

35%
34%
26%
25%
4

to host range protein of cowpox virus
to 27.4 kDa HindIII C protein of VV
to F8L protein of VV
to human brain ankyrin

35% to serotonin_ receptor of rat
35% to transcriptional factor Oct-1 in frog
33% to serotonin receptor of human

In order to further characterize the Pstl-L fragment, computer
assisted restriction analysis of the L fragment was done. Figure 5 shows
other restriction endonuclease sites within the Pstl-L fragment. There are
157 restriction sites within the Pstl-L fragment. The unique restriction
endonucleases (i.e. endonucleases that cut at one site within the L
fragment) are underlined in the following figure.
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DISCUSSION
In order to further to characterize TPV on a DNA sequence level,
we cloned approximately 17% of the TPV DNA genome into pUC19. Table
1 lists the clones and the TPV DNA fragment insert. Out of the 300
ampicillin-resistant colonies selected, only 116 contained TPV DNA
fragments. Many of the clones contained the same fragment (e.g. 46 of the
116 clones contained the PstI-L fragment). Overall, only 6 of the 15
possible PstI TPV DNA fragments were successfully cloned (Figure 1). The
two end terminal fragments of the TPV genome could not be cloned using
the 'shot gun' method due to the terminal ends being joined by hair-pin
loops. Some fragments were not successfully cloned into pUC19 most
likely because of their size. One exception is the PstI-K fragment (2.7 kbp).
This fragment co-migrates with PstI digest�d pUC19. The PstI-K fragment
may have been successfully cloned (clones 5, 58, 84, 100, 131, 335, 343, 347,
383,384,and 444),but could not be detected by gel electrophoresis.
Traktman et al. (1990) have previously reported that in VV the
essential genes are clustered in the middle of the genome whereas
virulence markers, which play a role in pathogenesis, are located near the
termini. Some of these virulence markers are thought to be proteins that
mimic host cell immune functions thereby increasing the viruses
survival in the host. With these concepts in mind, the 2.1 kbp PstI-L
cloned fragment was chosen for sequencing due to its relatively short
length and proximity to the end of the TPV genome. Before sequencing, a
36

37
Southern blot was done in order to verify that the cloned fragment was of
TPV genomic origin (Figure 2).
The complete Pstl-L DNA fragment (clone #36) from TPV was
sequenced (Figure 3). The predicted amino acid sequence and putative
ORFs were analyzed using IntelliGenetics software. Potentially, there are
37 complete ORFs and 1 partial ORF within this fragment.

Further

analysis of the 9 largest ORFs are shown in Figure 4 and listed in Table 2.
Analysis of the DNA sequence and proposed prot�in coding regions
required assumptions which may generate possible sources of error. One
assumption was there would not be any proteins within the L fragment
that were less than 4 kDa. The decision to establish probable amino acid
comparison of only the 9 largest ORFs (MW �4 kDa) was based on the
understanding that most VV proteins have molecular weights greater
than 7 kDa (Goebel, Johnson, Perkus, Davis, Winslow & Paoletti, 1990).
This decision may be an underestimate, but only further mRNA analysis
from TPV-infected cells will determine if this is true.
In order to minimize DNA sequence error, a minimum of three
gels were done on a specific region in order to verify the sequence. There
were problems with secondary structures in certain regions of the
fragment. In order to sequence through these areas we tried two different
approaches. One was to use the Taq DNA polymerase in the sequencing
reactions. This polymerase is stable at high temperatures. This allowed
the reactions to be done at higher temperatures thereby relaxing the
secondary structure. All attempts with this procedure failed. We then
used different primers further upstream of the region of interest. This
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procedure was successful in all cases except for the last 430 base pairs. This
region of the Pstl-L fragment has been verified in one direction, multiple
times.
Comparison of the ORF amino acid sequences revealed that most of
the putative ORFs within the Pstl-L fragment show a certain degree of
homology to proteins which function in cellular growth and
development. The largest ORF Pst-L4R (27 kDa) shows a relatively high
degree of homology to human erythrocyte ankryin (27%) which contains
repeated structures that have homology to tissue differentiation and cell
cycle control proteins (Lux, John & Bennett, 1990). It also shows homology
to the Ml protein of VV (30% in 40 amino acids), which is involved in
drug resistance to a-amanitin (Tamin, Villarreal, Weinrich & Hruby,
1988). Similarly, ORF Pst-L7R (17 kDa) also shows homology to the Ml
protein of VV (26%) and to human erythrocyte ankryin (26%). Given that
these two ORFs are translated in the same frame suggests that they may be
one continuous ORF. This would be possible if there was a base pair
substitution at base number 1322, thereby changing the termination site of
ORF Pst-L4R. Further sequence analysis of this region showed this is not
the case.
Another interesting ORF is Pst-L9L which shows a high degree of
homology to the serotonin receptor of rat and human. This ORF also has
a high percentage of hydrophobic amino acids (54% of the 37 amino acids)
suggesting that it may be a membrane bound protein. Two other ORFs
that are of interest,· Pst-LSL and Pst-L6R, have homology to growth factor
proteins. ORF Pst-LSL shows 30% homology to insulin-like rat growth
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factor IA which is structurally and functionally related to insulin but has a
much higher growth-promoting activity (Shimatsu & Rotwein, 1987).
ORF Pst-L6R shows a 25% homology to transforming growth factor B-5 of
frog (Kondaiah et al., 1990).
Some of the ORFs show amino acid homology to other poxviruses.
ORF Pst-L4R has 31% homology to BamHI ORF 13 of fowlpox virus
(Tomley, Binns, Campbell & Boursnell, 1988). ORFs Pst-L4R and Pst-L7R
both have 25% homology to B4R protein of VV which is related to the
tumor necrosis factor receptor family (Howard, Chen & Smith, 1991). ORF
Pst-L8R has a 35% homology to a host range protein of cowpox virus. This
protein enables cowpox virus to multiply in Chinese hamster ovary cells
(Spehner, Gillard, Drillien & Kirn, 1988).
Restriction analysis of the Pstl-L fragment using the IntelliGenetics
software is shown in Figure 5.

This data will be helpful to further

subclone the Pstl-L fragment for future DNA and RNA analyses.
Ultimately, the goal of this type of research is to identify gene
products. We have only begun, in this study, to characterize TPV at the
DNA level. Although no significant degree of homology to other known
virulence marker proteins were found within the Pstl-L fragment, further
analysis of other TPV Pstl fragments may show otherwise. Studying these
types of proteins will help in understanding viral pathogenesis and host
cell immune response to infection.
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